Stocks · News reference
A September filing shows that Representative Pete Sessions reported a sale in Apple (NASDAQ:AAPL), valued between $100,001 and $250,000. The transaction date is listed as September 22, 2026, with the report published on
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
A stock market analyst recommends a straightforward approach for new investors: open a zero-fee brokerage account, start with 10 familiar stocks, maintain balanced diversification, and use dollar-cost averaging to mitigate timing risk. The strategy emphasizes long-term wealth building over decades rather than quick gains.
The article compares AppLovin and Reddit as digital advertising investment opportunities. AppLovin boasts higher profitability with 60.8% net margins and $5.5B in FY2025 revenue, but faces legal challenges and competitive pressures. Reddit shows strong growth with 69.4% YoY revenue increase, newly achieved profitability, and a unique AI data licensing business. The author recommends Reddit for its durable growth foundation, unique data assets, and consistent user engagement, despite AppLovin's superior margins.
Apple stock is projected to deliver approximately 12% annualized returns over the next four years, potentially growing a $1,000 investment to about $1,464 by September 2030. Despite past concerns about missing the AI boom, Apple's strong position in consumer hardware, expanding services business, new Siri AI, and high-margin business model position it well to continue outperforming the S&P 500.
Meta's Muse AI assistant is fueling Meta's rally, while leveraged ETFs METG and METU are amplifying the move. Here's what the catalysts show.
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
The global skin boosters market is experiencing significant growth driven by increasing consumer demand for minimally invasive aesthetic procedures. The market, valued at $1.40 billion in 2025, is projected to reach $4.30 billion by 2035, with a CAGR of 11.89%. Growth is fueled by expanding medspa access, regenerative ingredients like PDRN, and rising awareness of hyaluronic acid treatments. The U.S. market is expected to grow from $0.36 billion to $1.08 billion, while Asia Pacific shows the highest growth potential at 12.70% CAGR.